Doubled dosage of sofosbuvir is expected for inhibiting Zika virus infection

Somsri Wiwanitkit; Viroj Wiwanitkit

doi:10.1016/j.apjtm.2017.06.012

Doubled dosage of sofosbuvir is expected for inhibiting Zika virus infection

Asian Pac J Trop Med. 2017 Jun;10(6):612-613. doi: 10.1016/j.apjtm.2017.06.012. Epub 2017 Jun 15.

Authors

Somsri Wiwanitkit¹, Viroj Wiwanitkit²

Affiliations

¹ Wiwanitkit House, Bangkhae, Bangkok Thailand. Electronic address: somsriwiwan@hotmail.com.
² Hainan Medical University, China; Dr DY Patil University, India; Faculty of Medicine, University of Nis, Serbia; Joseph Ayobabalola University, Nigeria.

PMID: 28756928
DOI: 10.1016/j.apjtm.2017.06.012

Abstract

Sofosbuvir is a new antiviral drug that has been recommended for management of hepatitis C virus (HCV) for a few years. New researches support that sofosbuvir might be useful for the management of Zika virus infection. Based on the pharmacological activity, inhibiting the HCV RNA-dependent RNA polymerase (RdRp or NS5 protein), sofosbuvir is proposed for its effectiveness against Zika virus infection. Here, the authors used a mathematical modelling theoretical approach to predict the expected dosage of sofosbuvir for inhibiting Zika virus infection. Based on the modeling study, if sofosbuvir is assigned for management of Zika virus infection, doubled dosage of the present dosage for hepatitis C management is recommended.

Keywords: Dosage; Inhibiting; Sofosbuvir; Zika virus.